ReviewMolecular diagnosis & therapy2013
Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics.
Review in Molecular diagnosis & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 55 citations in OpenAlex.
- Oncohepatology: Navigating liver injury in the era of modern cancer therapy.World journal of hepatology · 2025Review
- Serum glutamate dehydrogenase activity enables sensitive and specific diagnosis of hepatocellular injury in humans.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.Scientific reports · 2024Article
- Shining a light on liver health: advancements in fluorescence-enhanced enzyme biosensors for early disease detection.Frontiers in bioengineering and biotechnology · 2024Review
- The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.Metabolites · 2022Review
- Article
- Circulating microRNA Profiles in Acetaminophen Toxicity.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2020Observational
- Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments.PloS one · 2020Article
- Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort.PLoS computational biology · 2019Article
- Extracellular vesicles as potential biomarkers for alcohol- and drug-induced liver injury and their therapeutic applications.Pharmacology & therapeutics · 2018Review
- MicroRNAs as biomarkers for clinical studies.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.PloS one · 2018Article
- Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury.European journal of clinical pharmacology · 2017Review
- New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease.Frontiers in pharmacology · 2017Article
- Effect of amlodipine, lisinopril and allopurinol on acetaminophen-induced hepatotoxicity in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2016Article
- The past and present of serum aminotransferases and the future of liver injury biomarkers.EXCLI journal · 2016Review
- Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury.Genome medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) remains a rare but serious complication in drug therapy that is a primary cause of drug failure during clinical trials. Conventional biomarkers, particularly the serum transaminases and bilirubin, serve as useful indicators of hepatocellular or cholestatic liver injury, respectively, but only after substantial and sometimes irreversible tissue damage. Ideally, more sensitive biomarkers that respond very early before irreversible injury has occurred would offer improved outcomes. Novel biomarkers are initially being developed in animal models exposed to intrinsically hepatotoxic stimuli. However, the eventual translation to human populations, even those with known risk factors that predispose the liver to drug toxicity, would be the fundamental goal. Ultimately, some might even be applicable for the early identification of individuals predisposed to idiosyncratic hepatotoxicity potential. This article reviews recent progress in the discovery and qualification of novel biomarkers for DILI and delineates the path to eventual utilization for risk assessment. Some major categories of plasma or serum biomarkers surveyed include proteins, cytokines, circulating mRNAs, and microRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.